Die aktuellen Publikationen.

Link für alle Publikationen

 

- Prof. G. Ciarimboli: Publication list -

 

 

  1. Steinbüchel M, Menne J, Schröter R, Neugebauer U, Schlatter E, Ciarimboli G. Regulation of Transporters for Organic Cations by High Glucose. Int. J. Mol. Sci. 2023, 24, 14051. doi.org/10.3390/ijms241814051
  2. Hucke A, Schröter R, Ceresa C, Chiorazzi A, Canta A, Semperboni S, Marmiroli P, Cavaletti G, Gess B, Ciarimboli G. Role of Mouse Organic Cation Transporter 2 for Nephro- and Peripheral Neurotoxicity Induced by Chemotherapeutic Treatment with Cisplatin. Int. J. Mol. Sci. 2023, 24(14):11486. doi: 10.3390/ijms241411486.
  3. Ciarimboli G. Overcoming Biological Barriers: Importance of Membrane Transporters in Homeostasis, Disease and Disease Treatment. Int. J. Mol. Sci. 2023, 24(8):7212. doi: 10.3390/ijms24087212.
  4. Kroll MK, Schloer S, Candan P, Korthals N, Wenzel C, Ihle H, Gilhaus K, Liedtke KR, Schöfbänker M, Surmann B, Schröter R, Neugebauer U, Mall G, Oswald S, Ludwig S, Rescher U, Vollenbröker B, Ciarimboli G. Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells. Biomolecules. 2023, 13(3):472. doi: 10.3390/biom13030472.
  5. Kantauskaitė M, Hucke A, Snieder B, Ciarimboli G. Exacerbation of cisplatin cellular toxicity by regulation of the human organic cation transporter 2 through angiotensin II. Int. J. Mol. Sci. 2022,14;23(24):15866. doi: 10.3390/ijms232415866.
  6. Harrach S, Haag J, Steinbüchel M, Schröter R, Neugebauer U, Bertrand J, Ciarimboli G. Interaction of Masitinib with Organic Cation Transporters. Int. J. Mol. Sci. 2022, 16;23(22):14189. doi: 10.3390/ijms232214189.
  7. Ciarimboli G. Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations 2.0 (Editorial). Int. J. Mol. Sci. 2022, 23(11), 6328; doi.org/10.3390/ijms23116328
  8. Palatini M, Müller SF, Kirstgen M, Leiting S, Lehmann F, Soppa L, Goldmann N, Müller C, Lowjaga KAAT, Alber J, Ciarimboli G, Ziebuhr J, Glebe D, Geyer J. IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection. Viruses. 2022; 14(4):727. doi.org/10.3390/v14040727
  9. Ahmed Eltayeb S, Ciarimboli G, Beul K, Seno Di Marco G, Barz V. Role of Organic Cation Transporter 2 in Autophagy Induced by Platinum Derivatives. Int. J. Mol. Sci. 2022, 23,1090. doi.org/10.3390/ijms23031090
  10. Berghaus C, Groh AC, Breljak D, Ciarimboli G, Sabolic I, Pavenstädt H, Weide T. Impact of Pals1 on expression and localization of transporters belonging to the solute carrier family (SLC) Frontiers in Molecular Biosciences. 2022, 16;9:792829. doi: 10.3389/fmolb.2022.792829
  11. Plotnikov E, Ciarimboli G. Mitochondria in Renal Health and Disease Volume II (Editorial) Front Physiol. 2022, 12:818421. doi.org/10.3389/fphys.2021.818421
  12. Sutter ML, Console L, Fahner A-F, Samodelov SL, Gai Z, Ciarimboli G, Indiveri C, Kullak-Ublick GA, Visentin M. The role of cholesterol recognition (CARC/CRAC) mirror codes in the allosterism of the human organic cation transporter 2 (OCT2, SLC22A2). Biochemical Pharmacology 2021,194:114840. doi: 10.1016/j.bcp.2021.114840
  13. Ciarimboli G.Anticancer Platinum Drugs Update (Editorial) Biomolecules 2021, 11(11), 1637; doi.org/10.3390/biom11111637
  14. Koepp TN, Tokaj A, Nedvetsky PI, Conchon Costa AC, Snieder B, Schröter R, Ciarimboli G.Properties of transport mediated by the human organic cation transporter 2 studied in a polarized three-dimensional epithelial cell culture model. Int J Mol Sci. 2021; Vol. 22, Issue 17, 9658
  15. Plotnikov E, Ciarimboli G.Mitochondria in Renal Health and Disease (Editorial) Front Physiol. 2021 Jul 30;12:707175. doi: 10.3389/fphys.2021.707175.
  16. Schorn S, Dicke AK, Neugebauer U, Schröter R, Friedrich M, Reuter S, Ciarimboli G. Expression and function of organic cation transporter 2 in pancreas. Front. Cell Dev. Biol. - Cellular Biochemistry. 2021, 9:688885. doi: 10.3389/fcell.2021.688885.
  17. Money ME, Hamroun A, Shu Y, Matthews C, Ahmed Eltayeb S, Ciarimboli G, Metz CN. Case Report and Supporting Documentation: Acute Kidney Injury Manifested as Oliguria Is Reduced by Intravenous Magnesium Before Cisplatin. Front Oncol 2021; 26;11:60757.doi: 10.3389/fonc.2021.607574.
  18. Lepa C, Hoppe S, Stöber A, Skryabin BV, Sievers LK, Heitplatz B, Ciarimboli G, Neugebauer U, Lindenmeyer M, Cohen C, Drexler H, Boor P, Weide T, Pavenstädt H, and George G. TrkC is essential for nephron function and trans-activates Igf1R signaling; JASN 2021; 32(2):357-374. doi: 10.1681/ASN.2020040424.
  19. Hernández-Lozano I, Mairinger S, Sauberer M, Stanek J, Filip T, Wanek T, Ciarimboli G, Tournier N, Langer O. Influence of cation transporters (OCTs and MATEs) on the renal and hepatobiliary disposition of [11C]metoclopramide in mice. Pharm. Res. 2021;38(1):127-140. doi: 10.1007/s11095-021-03002-2
  20. Ciarimboli G. Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations (Editorial). Int J Mol Sci. 2021;22(2):732. doi: 10.3390/ijms22020732
  21. Amrhein J, Drynda S, Schlatt L, Karst U, Lohmann CH, Ciarimboli G, Bertrand J. Tofacitinib and Baricitinib are taken up by different uptake mechanisms determining the efficacy of both drugs in RA. Int J Mol Sci 2020; 21, 6632; doi:10.3390/ijms21186632
  22. Ciarimboli G. Fishing for protective compounds.eLife 2020;9:e61547. doi: doi.org/10.7554/eLife.61547
  23. Kantauskaitė M, Hucke A, Reike M, Ahmed Eltayeb S, Xiao C, Barz V, Ciarimboli G. Rapid regulation of human multidrug and extrusion transporters hMATE1 and hMATE2K. Int J Mol Sci 2020Jul 21;21(14):E5157. doi: 10.3390/ijms21145157.
  24. Schlatt L, Conchon Costa AC, Barz V, Ciarimboli G, Karst U. Fast simultaneous quantification of gabapentin and cetirizine in cell lysates by means of HPLC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2020, 184:113172. doi: 10.1016/j.jpba.2020.113172.
  25. Conchon Costa AC, Yamamoto PA, Lauretti GR, de Lima Benzi JR, Zanelli CF, Barz V, Ciarimboli G, de Moraes NV. Cetirizine reduces gabapentin plasma concentrations and effect: role of renal drug transporters for organic cations. The Journal of Clinical Pharmacology, 2020, 60(8):1076-1086. doi: 10.1002/jcph.1603.
  26. Oswald S, Müller J, Neugebauer U, Schröter R, Herrmann E, Pavenstädt H and Ciarimboli G.Protein Abundance of Clinically Relevant Drug Transporters in The Human Kidneys.Int J Mol Sci 2019, 20, 5303; doi:10.3390/ijms20215303.
  27. Frenzel D, Köppen C, Bauer OB, Karst U, Schröter R, Tzvetkov MV, Ciarimboli G.Effects of Single Nucleotide Polymorphism Ala270Ser (rs316019) on the Function and Regulation of hOCT2.Biomolecules. 2019; 7;9(10). pii: E578. doi: 10.3390/biom9100578.
  28. Hucke A, Rinschen MM, Bauer OB, Sperling M, Karst U, Köppen C, Sommer K, Schröter R, Ceresa C, Chiorazzi A, Canta A, Semperboni S, Marmiroli P, Cavaletti G, Schlatt S, Schlatter E, Pavenstädt H, Heitplatz B, Van Marck V, Sparreboom A, Barz V, Knief A, Deuster D, Zehnhoff-Dinnesen AA, Ciarimboli G.An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection.Arch Toxicol. 2019;93(10):2835-2848. doi: 10.1007/s00204-019-02557-9.
  29. Snieder B, Brast S, Grabner A, Buchholz S, Schröter R, Spoden GA, Florin L, Salomon J, Albrecht T, Barz V, Sparreboom A, Ciarimboli G.Identification of the Tetraspanin CD9 as an Interaction Partner of Organic Cation Transporters 1 and 2.SLAS Discov. 2019;24(9):904-914. doi: 10.1177/2472555219859837
  30. Späth MR, Bartram MP, Palacio-Escat N, Hoyer KJR, Debes C, Demir F, Schroeter CB, Mandel AM, Grundmann F, Ciarimboli G, Beyer A, Kizhakkedathu JN, Brodesser S, Göbel H, Becker JU, Benzing T, Schermer B, Höhne M, Burst V, Saez-Rodriguez J, Huesgen PF, Müller RU, Rinschen MM. The proteome microenvironment determines the protective effect of preconditioning in cisplatin-induced acute kidney injury. Kidney Int. 2019;95(2):333-349. doi: 10.1016/j.kint.2018.08.037.
  31. Bauer OB, Hachmöller O, Borovinskaya O, Sperling M, Schurek HJ, Ciarimboli G, Karst U. LA-ICP-TOF-MS for rapid, all-elemental and quantitative bioimaging, isotopic analysis and the investigation of plasma processes. J. Anal. At. Spectrom., 2019, 34, 694. doi: 10.1039/c8ja00288f.
  32. Harrach S, Barz V, Pap T, Pavenstädt H, Schlatter E, Edemir B, Distler J, Ciarimboli G*, Bertrand J*: Notch-signaling activity determines uptake and biological effect of imatinib in systemic sclerosis dermal fibroblasts. J Invest Dermatol. 2018; pii: S0022-202X(18)32642-3. doi: 10.1016/j.jid.2018.08.021. * geteilte Senior-Autorenschaft
  33. Michgehl U, Skryabin BV, Bayraktar S, Vollenbröker B, Ciarimboli G, Heitplatz B, Van Marck V, Gröne HJ, Pavenstädt H, Weide T: Nephron specific knockin of the PIKfyve binding deficient Vac14L156R mutant results in albuminuria and mesangial expansion. Am J Physiol Renal Physiol. 2018. 315(5): F1307-F1319. doi: 10.1152/ajprenal.00191.2018.
  34. Hucke A, Park GY, Bauer OB, Beyer G, Köppen C, Zeeh D, Wehe CA, Sperling M, Schröter R, Kantauskaitè M, Hagos Y, Karst U, Lippard SJ, Ciarimboli G: Interaction of the new monofunctional anticancer agent Phenanthriplatin with transporters for organic cations. Front Chem. 2018; 6:180. doi: 10.3389/fchem.2018.00180.
  35. Bauer OB, Köppen C, Sperling M, Schurek HJ, Ciarimboli G, Karst U: Quantitative bioimaging of platinum via online isotope dilution-laser ablation-inductively coupled plasma mass spectrometry.Anal Chem. 2018; 90(11):7033-7039. doi: 10.1021/acs.analchem.8b01429.
  36. Höhne M, Frese CK, Grahammer F, Dafinger C, Ciarimboli G, Butt L, Binz J, Hackl MJ, Rahmatollahi M, Kann M, Schneider S, Altintas MM, Schermer B, Reinheckel T, Göbel H, Reiser J, Huber TB, Kramann R, Seeger-Nukpezah T, Liebau MC, Beck BB, Benzing T, Beyer A, Rinschen MM: Single nephron proteomes connect morphology and function in proteinuric kidney disease. Kidney Int. 2018; 93(6):1308-1319. doi: 10.1016/j.kint.2017 IF 2016: 8,395.
  37. Guttmann S, Chandhok G, Reinartz Groba S, Niemietz C, Sauer V, Gomes A, Ciarimboli G, Karst U, Zibert A, Schmidt HH. Organic cation transporter 3 mediates cisplatin and copper cross-resistance in hepatoma cells. Oncotarget 2017; 12;9(1):743-754. doi: 10.18632/oncotarget.2314.
  38. Schelleckes K, Schmitz B, Ciarimboli G, Lenders M, Pavenstädt HJ, Herrmann E, Brand SM, Brand E. Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinoma. Clin Epigenetics. 2017; 9:109. doi: 10.1186/s13148-017-0415-6.
  39. Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens JHM, Baker SD, Pabla N and SparreboomA. Identification of OAT1/OAT3 as contributors to cisplatin toxicity.Clin Transl Sci 2017; 00, 1–9; doi:10.1111/cts.12480.
  40. Harrach S, Edemir B, Schmidt-Lauber C, Pap T, Bertrand J, Ciarimboli G.Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts.Sci Rep. 2017;7(1):1258. doi: 10.1038/s41598-017-01438-4.
  41. Schulze U, Brast S, Grabner A, Albiker C, Snieder B, Holle S, Schlatter E, Schröter R, Pavenstädt H, Herrmann E, Lambert C, Spoden GA, Florin L, Saftig P, Ciarimboli G.Tetraspanin CD63 controls basolateral sorting of organic cation transporter 2 in renal proximal tubules.FASEB J. 201731(4):1421-1433. doi: 10.1096/fj.201600901R.
  42. Harrach S, Schmidt-Lauber C, Pap T, Pavenstädt H, Schlatter E, Schmidt E, Berdel WE, Schulze U, Edemir B, Jeromin S, Haferlach T, Ciarimboli G*, Bertrand J*. MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients.Blood Cancer J. 2016; 6:e470. doi: 10.1038/bcj.2016.79.* geteilte Senior-Autorenschaft
  43. Schulze Blasum B, Schröter R, Neugebauer U, Hofschröer V, Pavenstädt H, Ciarimboli G, Schlatter E, Edemir B. The kidney-specific expression of genes can be modulated by the extracellular osmolality.FASEB J. 2016; 30(10):3588-3597. pii: fj.201600319R.
  44. Ciarimboli G. In reference to immunohistochemical localization of OCT2 in the cochlea of various species.Laryngoscope. 2016; 126(6):E231. doi: 10.1002/lary.25881.
  45. Sprowl J, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SO, Diasio RB,Nies A, Schwab M, Cavaletti G, Schlatter E, CiarimboliG, Schellens JHM, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. A phosphotyrosine switch regulates organic cation transporters. Nature Communications, 2016, 7:10880 doi: 10.1038/ncomms10880.
  46. Köppen C, Reifschneider O, Castanheira I, Sperling M, Karst U, Ciarimboli G. Quantitative imaging of platinum based on laser ablation inductively coupled plasma-mass spectrometry to investigate toxic side effects of cisplatin. Metallomics, 2015, 7(12):1595-603.
  47. Thelen S, Abouhamed M, Ciarimboli G, Edemir B, Bähler M. The Rho GAP Myosin IXa is a regulator of kidney tubule function. Am J Physiol Renal Physiol. 2015, 309(6):F501-13 doi: 10.1152/ajprenal.00220.2014.
  48. Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jürgens H, Am Zehnhoff-Dinnesen AG, Sparreboom A, Ciarimboli G. Human organic cation transporter 2 variant c.808G>T carriers confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics, 2015, 16, (4): 323-332
  49. Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LI, Schlatter E, Chen T, Ciarimboli G, Sparreboom A. Mitigation of acute kidney injury by cell cycle inhibitors that suppress both CDK4/6 and OCT2 functions Proc Natl Acad Sci USA, 2015, 12(16):5231-5236.  
  50. Wehe CA, Thyssen GM, Herdering C, Raj I, Ciarimboli G, Sperling M, Karst U. Elemental bioimaging by means of fast scanning laser ablation-inductively coupled plasma-mass spectrometry. Journal of The American Society for Mass Spectrometry, 2015, 26(8):1274-82. doi: 10.1007/s13361-015-1141-y
  51. Sprowl JA, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA, Li L, Zeeh D, Schlatter E, Janke LJ, Ciarimboli G, Sparreboom A. Cisplatin-induced renal injury is independently mediated by OCT2 and p53. Clin Cancer Res. 2014,20(15):4026-35.
  52. Baumann D, Amann K, Schlatter E, Ciarimboli G, Kopp HG, Müller M, Kluba T, Bakos G, Steinke I, Bunz H, Weyrich P, Artunc F. [End-stage renal disease after sarcoma therapy - case 3/2014]. Dtsch Med Wochenschr. 2014, 139(15):785.
  53. Lanvers-Kaminsky C, Malath I, Deuster D, Ciarimboli G, Boos J, Am Zehnhoff-Dinnesen AG. Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity. Clin Pharmacol Ther. 2014, 96(2):156-7.
  54. Wehe CA, Beyer G, Sperling M, Ciarimboli G, Karst U. Assessing the intracellular concentration of platinum in medulloblastoma cell lines after Cisplatin incubation. J Trace Elem Med Biol. 2014, 28(2):166-72.
  55. Schlatter E, Klassen P, Massmann V, Holle SK, Guckel D, Edemir B, Pavenstädt H, Ciarimboli G: Mouse organic cation transporter 1 determines properties and regulation of basolateral organic cation transport in renal proximal tubules Pflügers Arch 2013, 466(8):1581-9.
  56. Herdering C, Wehe CA, Reifschneider O, Raj I, Ciarimboli G, Diebold K, Becker C, Sperling M, and Karst U: Laser ablation based bioimaging with simultaneous elemental and molecularmass spectrometry: towards spatially resolved speciation analysis. Rapid Commun Mass Spectrom 2013, 27, 2588–2594.
  57. Massmann V, Edemir B, Schlatter E, Al-Monajjed R, Harrach S, Klassen P, Holle SK, Sindic A, Dobrivojevic M, Pavenstädt H, Ciarimboli G: The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflügers Arch 2014, 466(3):517-27. DOI: 10.1007/s00424-013-1335-8
  58. Reifschneider O, Wehe CA, Raj I, Ehmcke J, Ciarimboli G, Sperling M, Karst U. Quantitative bioimaging of platinum in polymer embedded mouse organs using laser  ablation ICP-MS. Metallomics 2013; 5(10):1440-1447.
  59. Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci USA 2013; 110(27):11199-11204.
  60. Thévenod F, Ciarimboli G, Leistner M, Wolff NA, Lee WK, Schatz I, Keller T, Al-Monajjed R, Gorboulev V, Koepsell H. Substrate- and cell contact-dependent inhibitor affinity of human organic cation transporter 2: studies with two classical organic cation substrates and the novel substrate Cd(2+). Mol Pharm 2013;10(8):3045-3056.
  61. Ciarimboli G, Schröter R, Neugebauer U, Vollenbröker B, Gabriëls G, Brzica H, Sabolić I, Pietig G, Pavenstädt H, Schlatter E, Edemir B. Kidney transplantation down-regulates expression of organic cation transporters, which translocate β-blockers and fluoroquinolones. Mol Pharm 2013; 10(6):2370-2380.
  62. Schmidt-Lauber C, Harrach S, Pap T, Fischer M, Victor M, Heitzmann M, Hansen U, Fobker M, Brand SM, Sindic A, Pavenstädt H, Edemir B, Schlatter E, Bertrand J, Ciarimboli G. Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis. PLoS One 2012; 7(12):e52247.
  63. Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstädt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A: Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 2012; 15;18(4):1101-1108.
  64. Brast S, Grabner A, Sucic S, Sitte HH, Hermann E, Pavenstädt H, Schlatter E, Ciarimboli G: The cysteines of the extracellular loop are crucial for trafficking of human organic cation transporter 2 to the plasma membrane and are involved in  oligomerization. FASEB J 2012; 26(3):976-986.
  65. Guckel D, Ciarimboli G, Pavenstädt H, Schlatter E: Regulation of organic cation transport in isolated mouse proximal tubules involves complex changes in protein trafficking and substrate affinity. Cell Physiol Biochem 2012; 30(1):269-281.
  66. Grabner A, Brast S, Sucic S, Bierer S, Hirsch B, Pavenstädt H, Sitte HH, Schlatter E, Ciarimboli G: LAPTM4A interacts with hOCT2 and regulates its endocytotic recruitment. Cell Mol Life Sci 2011; 68(24):4079-4090.
  67. Holle SK, Ciarimboli G, Edemir B, Neugebauer U, Pavenstädt H, Schlatter E: Properties and regulation of organic cation transport in freshly isolated mouse proximal tubules analyzed with a fluorescence reader-based method. Pflügers Arch 2011; 462(2):359-369.
  68. Ciarimboli G, Holle SK, Vollenbröcker B, Hagos Y, Reuter S, Burckhardt G, Bierer S, Herrmann E, Pavenstädt H, Rossi R, Kleta R, Schlatter E: New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol Pharm 2011; 7;8(1):270-279.
  69. Ehrsson H, Wallin ICiarimboli G, Schlatter E: Cimetidine as an organic cation transporter antagonist. Am J Pathol 2010; 177(3):1573-1574.
  70. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Jürgens H, Schlatter E: Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is target for protective interventions. Am J Pathol 2010; 176(3), 1169-1180.
  71. Lee WK, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H, Thévenod F: Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 2009; 296(6): F1504-1513.
  72. Wilde S, Schlatter E, Koepsell H, Edemir B, Reuter S, Pavenstädt H, Neugebauer U, Schröter R, Brast S, Ciarimboli G: Calmodulin-associated post-translational regulation of rat organic cation transporter 2 in the kidney is gender dependent. Cell Mol Life Sci 2009; 66(10):1729-1740.
  73. Ciarimboli G: Unraveling the ceramide-calpain-caspase connection in cadmium-induced apoptosis: a novel role for ceramides as activators of calpains. Focus on "Cadmium-induced ceramide formation triggers calpain-dependent apoptosis in cultured kidney proximal tubule cells". Am J Physiol Cell. Physiol 2007; 293(3):C837-838 (Editorial Focus)
  74. Sturm A, Gorboulev V, Gorbunov D, Keller T, Volk C, Schmitt BM, Schlachtbauer P, Ciarimboli G, Koepsell H. Identification of cysteines in rat organic cation transporters rOCT1 (C322, C451) and rOCT2 (C451) critical for transport activity and substrate affinity. Am J Physiol Renal Physiol 2007; 293(3): F767-79
  75. Biermann J, Lang D, Gorboulev V, Koepsell H, Sindic A, Schröter R, Zvirbliene A, Pavenstädt H, Schlatter E, Ciarimboli G. Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol 2006; 290(6):C1521-31.
  76. Schlatter E, Ciarimboli G. Insights into regulatory mechanisms of organic cation transporters Acta Biomed 2006; 77; Suppl. 3: 30-31
  77. Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167(6):1477-1484.
  78. Ciarimboli G, Koepsell H, Iordanova M, Gorboulev V, Dürner B, Lang D, Edemir B, Schröter R, Van Le T, Schlatter E: Individual PKC- phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 2005; 16:1562-1570.
  79. Ciarimboli G, Struwe K, Arndt P, Gorboulev V, Koepsell H, Schlatter E, Hirsch JR: Regulation of the human organic cation transporters hOCT1. J Cell Physiol 2004; 201:420-428.
  80. Ciarimboli G, Hjalmarsson C, Bokenkamp A, Schurek HJ, Haraldsson B: Dynamic alterations of glomerular charge density in fixed rat kidneys suggest involvement of endothelial cell coat. Am J Physiol Renal Physiol 2003; 285(4): F722-30.
  81. Cetinkaya I, Ciarimboli G, Yalcinkaya G, Mehrens T, Velic A, Hirsch JR, Gorboulev V, Koepsell H, Schlatter E: The human organic cation transporter hOCT2 is regulated by Ca2+/calmodulin-, cAMP- and phosphatidylinositol-3-dependent kinases. Am J Physiol Renal Physiol 2003; 284(2): F293-302.
  82. Schlatter E, Monnich V, Cetinkaya I, Mehrens T, Ciarimboli G, Hirsch JR, Popp C, Koepsell H: The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP. J Membr Biol 2002; 189(3): 237-244.
  83. Ciarimboli G, Bökenkamp A, Schurek HJ, Fels LM, Kilian I, Maess B, Stolte H: The "fixed" charge of glomerular capillary wall as determinant of permselectivity. Ren Fail 2001; 23 (3-4): 365-76.
  84. Bökenkamp A, Ciarimboli G, Dieterich C: Cystatin C in a rat model of end-stage renal failure. Ren Fail 2001; 23 (3-4): 431-8.
  85. Ciarimboli G, Schurek HJ, Zeh M, Flohr H, Bökenkamp A, Fels L, Kilian I and Stolte H: Role of albumin and glomerular capillary wall charge distribution on glomerular permselectivity. Studies in the perfused-fixed rat kidney model. Pflügers Archiv 1999; 438: 883-891.
  86. Miniati M, Paci A, Cocci F, Ciarimboli G, Monti S. and Pistolesi M: Mitochondria act as a Reservoir for the basic amine HIPDM in the Lung. Eur Resp J 1996; 9:11: 2306-2312.
  87. Paci A, Ciarimboli G, Biver P: Human placenta radioreceptor assay with Digoxin and Ouabain to detect endogenous digitalis-like factor(s) in human plasma and urine. Clin Chem 1996; 42:2; 270-278.
  88. Paci A, Ledda A, Ciarimboli G, Biver P, Bernini GP: Commercial enzyme immunoassay reagent pack for Ouabain compared with human placenta radioreceptor assay. Clin Chem 1996; 42:4; 648-650.
  89. Paci A, Cocci F, Niedermeyer HP, Piras F, Ciarimboli G, Vitali C, Bombardieri S: Demostration of ß1-adrenergic receptors in human placenta by (-) [125I]Iodocyanopindolol binding. J Nucl Med All Sci* 1989; 33: 15-21. *Heute erscheint als „The Quarterly Journal of Nuclear Medicine and Molecular Imaging“
  90. Cocci F, Clerico A, Paci A, Piras F, Del Chicca MG, Ciarimboli G, Strigini F, Moggi G: Radioreceptor assay for the measurement of endogenous digitalis-like factors using membrane particulate fraction of human placenta and 125I-Digoxin: Comparison with RIA method. J Nucl Med All Sci* 1990; 34: 24-28. *Heute erscheint als „The Quarterly Journal of Nuclear Medicine and Molecular Imaging“
  91. Paci A, Ciarimboli G, Miniati M, Cocci F, Piras F, Pistolesi M: Lung tissue binding of Iodobenzyl-Propanediamine: Involvement of Beta-adrenergic receptors. J Pharm Biomed Analysis 1989; 7: 1467-1472.
  92. Paci A, Cocci F, Ciarimboli G, Piras F, Tonelli A, Ghione S : Binding of 14C-Furosemide to isolated human erythrocytes. J Pharm Biomed Analysis 1989; 7: 1459-1465.
  93. Paci A, Cocci F, Piras F, Ciarimboli G, Clerico A: Specific binding of cardiac glycoside drugs and endogenous digitalis-like substances to particulate membrane fractions from human placenta. Clin Chem 1989; 35: 2093-2097.

 

Reviews

 

  1. Ciarimboli G. Regulation mechanisms of expression and function of organic cation transporter 1. Front. Pharmacol. 2021; 21;11:607613. doi: 10.3389/fphar.2020.607613
  2. Ciarimboli G, Theil G, Bialek J, Edemir B. Contribution and Expression of Organic Cation Transporters and Aquaporin Water Channels in Renal Cancer. Reviews of Physiology, Biochemistry and Pharmacology. Springer, Berlin, Heidelberg. 2021;181: 81-104. doi: 10.1007/112_2020_34
  3. Lanvers-Kaminsky C, Ciarimboli G.Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.Pharmacogenomics. 2017;18(18):1683-1695. doi: 10.2217/pgs-2017-0125.
  4. Lanvers-Kaminsky C, Am Zehnhoff-Dinnesen AG, Parfitt R, Ciarimboli G.Drug-induced Ototoxicity: Mechanisms, Pharmacogenetics, and Protective Strategies.Clin Pharmacol Ther. 2017;101(4):491-500. doi: 10.1002/cpt.603.3
  5. Hucke A, Ciarimboli G. The role of transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations. J Clin Pharmacol. 2016;56 Suppl 7:S157-72
  6. Harrach S and Ciarimboli G: Role of transporters in the distribution of platinum-based drugs. Frontiers in Pharmacology 2015, 6:85. doi: 10.3389/fphar.2015.00085
  7. Ciarimboli G: Membrane transporters as mediators of cisplatin side-effects. Anticancer Res. 2014; 34(1):547-550.
  8. Wensing KU, Ciarimboli G: Saving ears and kidneys from cisplatin. Anticancer Res. 2013;33(10):4183-4188.
  9. Ciarimboli G: Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 2011;7(2):159-174.
  10. Ciarimboli G. Organic cation transporters. Xenobiotica 2008; 38(7-8):936-971.
  11. Ciarimboli G and Schlatter E: Regulation of organic cation transport (Review). Pflügers Archiv 2005; 449:423-441.
  12. Paci A, Ciarimboli G, Ferdeghini M: Growth factors and oncogenes in development and carcinogenesis: Role of the epidermal growth factor receptor system. Minerva Medica 1994; 85: 467-490.

 

Books and Book Chapters:

 

  1. Ciarimboli G and Schlatter E: Organic cation transport measurements using fluorescence techniques pp173-188 In: Neurotransmitter Transporters Bönisch H and HH Sitte Eds; Humana Press Springer Nature, doi  10.1007/978-1-4939-3765-3, 2016
  2. Editor of the book: Organic Cation Transporters: Integration of Physiology, Pathology, and Pharmacology, Ciarimboli G, Gautron S, Schlatter E Eds; Springer International Publishing, doi: 10.1007/978-3-319-23793-0, 2016
  3. Ciarimboli G: Introduction to the cellular transport of organic cations pp 1-47 In: Organic Cation Transporters: Integration of Physiology, Pathology, and Pharmacology, Ciarimboli G, Gautron S, Schlatter E Eds; Springer International Publishing, doi: 10.1007/978-3-319-23793-0, 2016
  4. Ciarimboli G. Organic cation transporter 2 as mediators of cisplatin nephrotoxicity. pp 353-358 In: Platinum and other heavy metal compounds in cancer chemotherapy. Humana Press, New York, USA (2009) Editors Bonetti, Leone, Muggia, Howell
  5. Paci A, Ciarimboli G, Biver P, Pilo A: Radioreceptor assay: a tool for measuring unknown substances with digitalis-like activity. Proceedings of the 5th Symposium on Analysis of Steroids, in Advances in Steroid Analysis 93, Görög S Ed, Akadémiai Kiadò, Publishing House of the Hungarian Academy of Sciences, Budapest, 1993: 69-75
  6. Paci A, Neglia D, Ciarimboli G, Berti S, Pilo A, Baratto MT, Parodi O, L'Abbate A, Donato L: Anti-ß-receptor antibodies in patients with left bundle branch block or ventricular arrhythmias. New Trends in Arrhythmias 1991; VII: 979-985.